D
Dominick J. Angiolillo
Researcher at University of Florida
Publications - 741
Citations - 39889
Dominick J. Angiolillo is an academic researcher from University of Florida. The author has contributed to research in topics: Clopidogrel & Percutaneous coronary intervention. The author has an hindex of 92, co-authored 635 publications receiving 34262 citations. Previous affiliations of Dominick J. Angiolillo include Newcastle upon Tyne Hospitals NHS Foundation Trust & University of Barcelona.
Papers
More filters
Journal ArticleDOI
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Matthew J. Price,Peter B. Berger,Paul S. Teirstein,Jean-François Tanguay,Dominick J. Angiolillo,Douglas Spriggs,Sanjeev Puri,Mark Robbins,Kirk N. Garratt,Olivier F. Bertrand,Michael E. Stillabower,Joseph Aragon,David E. Kandzari,Curtiss T. Stinis,Michael S. Lee,Steven V. Manoukian,Christopher P. Cannon,Nicholas J. Schork,Eric J. Topol +18 more
TL;DR: In this paper, the authors evaluated the effect of high-dose compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity after percutaneous coronary intervention (PCI), but a treatment strategy for this issue was not well defined.
Journal ArticleDOI
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
Laurent Bonello,Udaya S. Tantry,Rossella Marcucci,Ruediger Blindt,Dominick J. Angiolillo,Richard C. Becker,Deepak L. Bhatt,Marco Cattaneo,Jean-Philippe Collet,Thomas Cuisset,Christian Gachet,Gilles Montalescot,Lisa K. Jennings,Dean J. Kereiakes,Dirk Sibbing,Dietmar Trenk,Jochem W. van Werkum,Franck Paganelli,Matthew J. Price,Ron Waksman,Paul A. Gurbel +20 more
TL;DR: A consensus opinion is provided on the definition of high on-treatment platelet reactivity to ADP based on various methods reported in the literature and how this measurement may be used in the future care of patients.
Journal ArticleDOI
Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives
Dominick J. Angiolillo,Antonio Fernández-Ortiz,Esther Bernardo,Fernando Alfonso,Carlos Macaya,Theodore A. Bass,Marco A. Costa +6 more
TL;DR: In this article, the impact of individual response variability to clopidogrel on clinical outcomes and current and future directions for its management is reviewed. But, despite the use of clopidine, a considerable number of patients continue to have cardiovascular events.
Journal ArticleDOI
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Stephen D. Wiviott,Dietmar Trenk,Andrew L. Frelinger,Michelle L. O'Donoghue,Franz-Josef Neumann,Alan D. Michelson,Dominick J. Angiolillo,Hanoch Hod,Gilles Montalescot,Debra L. Miller,Joseph A. Jakubowski,Richard Cairns,Sabina A. Murphy,Carolyn H. McCabe,Elliott M. Antman,Eugene Braunwald +15 more
TL;DR: Among patients undergoing cardiac catheterization with planned percutaneous coronary intervention, loading with 60 mg prasugrel resulted in greater platelet inhibition than a 600-mg clopidogrel loading dose.
Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention
Matthew J. Price,Peter B. Berger,Paul S. Teirstein,Dominick J. Angiolillo,Douglas Spriggs,Sanjeev Puri,Mark Robbins,Kirk N. Garratt,Olivier F. Bertrand,Michael E. Stillablower,Joseph Aragon,David E. Kandzari,Curtiss T. Stinis,Michael S. Lee,Steven V. Manoukian,Christopher P. Cannon,Nicholas J. Schork,Eric J. Topol +17 more
TL;DR: Among patients with high on-treatment reactivity after PCI with drug-eluting stents, the use of high-dose clopidogrel compared with standard- dose clopIDogrel did not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis.